Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Shahneen K SandhuJohann S de Bono

Abstract

Inbuilt mechanisms of DNA surveillance and repair are integral to the maintenance of genomic stability. Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that plays a critical role in DNA damage response processes. PARP inhibition has been successfully employed as a novel therapeutic strategy to enhance the cytotoxic effects of DNA-damaging agents. We have shown that PARP inhibition has substantial single agent antitumour activity with a wide therapeutic index in homologous DNA repair-defective tumours such as those arising in BRCA1 and BRCA2 mutation carriers. This is the first successful clinical application of a synthetic lethal approach to targeting cancer. Exploitation of defects in DNA repair pathways through targeted inhibition of salvage repair pathways is an exciting anticancer approach, with potentially broad clinical applicability. Several PARP inhibitors are now in clinical development. This review outlines the biological function and rationale of targeting PARP, details pre-clinical and clinical data and discusses the promises and challenges involved in developing these antitumour agents.

References

Sep 1, 1991·Mutation Research·B N Ames, L S Gold
Feb 7, 1980·Nature·B W DurkaczS Shall
Jan 1, 1999·Nature·C LengauerB Vogelstein
Jul 3, 1999·Trends in Biochemical Sciences·J E Haber
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·B H SpainI M Verma
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R MiddletonN Thatcher
Apr 6, 2000·Journal of the National Cancer Institute·M EstellerJ G Herman
Aug 1, 2000·Mutation Research·A Memisoglu, L Samson
May 18, 2001·Nature·J H Hoeijmakers
Feb 8, 2002·Cell·Ashok R Venkitaraman
Sep 19, 2002·Journal of the National Cancer Institute·Marcia S BroseBarbara L Weber
Feb 7, 2003·Current Medicinal Chemistry·Garry J Southan, Csaba Szabó
Apr 15, 2003·Nature Medicine·Toshiyasu TaniguchiAlan D D'Andrea
May 3, 2003·The EMBO Journal·Josiane Ménissier de MurciaGilbert de Murcia
Jun 6, 2003·The New England Journal of Medicine·Richard Wooster, Barbara L Weber
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Aug 22, 2003·Nucleic Acids Research·Niklas SchultzThomas Helleday
Apr 2, 1963·Biochemical and Biophysical Research Communications·P CHAMBONP MANDEL
Oct 2, 2003·Journal of the National Cancer Institute·William D FoulkesLars A Akslen
Dec 4, 2003·Cell·Luke Hughes-DaviesTony Kouzarides
Jan 8, 2004·Journal of the National Cancer Institute·Christopher R CalabreseNicola J Curtin
Jan 31, 2004·International Journal of Radiation Oncology, Biology, Physics·Anthony ChalmersBrian Marples
Feb 11, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·A J Chalmers
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Apr 20, 2005·Expert Reviews in Molecular Medicine·Nicola J Curtin
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·E Ruth PlummerNicola J Curtin
Aug 20, 2005·Nature Reviews. Cancer·William G Kaelin

❮ Previous
Next ❯

Citations

Sep 3, 2010·Cellular and Molecular Life Sciences : CMLS·David M Wilson, Anton Simeonov
Aug 21, 2010·Cellular and Molecular Life Sciences : CMLS·Frédérique Mégnin-ChanetJanet Hall
Mar 8, 2012·Apoptosis : an International Journal on Programmed Cell Death·Song-qiang XieChao-jie Wang
Dec 31, 2010·Cellular and Molecular Neurobiology·Graciela L Mazzone, Andrea Nistri
May 23, 2012·Investigational New Drugs·Nilesh A PatankarMarcel B Bally
Mar 2, 2011·International Journal of Hematology·Adam J LinleyRobert C Rees
Oct 17, 2013·Nature Reviews. Clinical Oncology·Joaquin MateoJohann S de Bono
Dec 22, 2011·The Pharmacogenomics Journal·M A Lowery, E M O'Reilly
Mar 21, 2012·Carcinogenesis·Fabricio G SousaJenifer Saffi
Oct 15, 2010·Science Translational Medicine·Konstantin J DedesJorge S Reis-Filho
Jan 17, 2012·Molecular Cancer Research : MCR·Padmini S KedarSamuel H Wilson
Aug 6, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Maeve A Lowery, Eileen M O'Reilly
Jan 5, 2011·Frontiers in Bioscience (Scholar Edition)·Amy R CarrollAnil K Sood
Apr 8, 2011·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Danny VespriniRobert G Bristow
Jul 6, 2014·Journal of Neuro-oncology·Manmeet S Ahluwalia, Susan M Chang
Sep 16, 2011·Expert Review of Anticancer Therapy·Sheeba IrshadAndrew Tutt
Sep 10, 2011·Clinical Colorectal Cancer·Eamon BergeWells Messersmith
Sep 30, 2010·Biochemical Pharmacology·Giovanna D'OnofrioPiera Quesada
Apr 27, 2010·Biochemical Pharmacology·Vincenzo GiansantiA Ivana Scovassi
Jun 20, 2015·Molecular Cell·Felix Y FengKaren E Knudsen
Sep 8, 2015·Bioorganic & Medicinal Chemistry Letters·Zhouling XieZhiyu Li
Jan 6, 2011·CA: a Cancer Journal for Clinicians·Timothy A YapJohann S de Bono
Sep 21, 2010·International Journal of Cancer. Journal International Du Cancer·Aswin Mangerich, Alexander Bürkle
Aug 12, 2014·The Prostate·Anna M JohnsonKathleen A Cooney
Aug 9, 2011·Biochemical and Biophysical Research Communications·Shuai WangZhi-Xiang Xu
May 24, 2011·Expert Opinion on Therapeutic Patents·Michael Lainchbury, Ian Collins
Jul 16, 2014·Biochimica Et Biophysica Acta·Barbara Lupo, Livio Trusolino
Aug 12, 2016·Endocrine-related Cancer·Louis de MestierPascal Hammel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Related Papers

Nature Reviews. Cancer
Michèle RouleauGuy G Poirier
Nature Reviews. Molecular Cell Biology
Valérie SchreiberG de Murcia
Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Lucio Tentori, Grazia Graziani
© 2022 Meta ULC. All rights reserved